US 12,263,185 B2
Hemostatic material and spray
Thomas Freier, Rhineland-Palatinate (DE); Rivelino Montenegro, Rhineland-Palatinate (DE); and Wayne Grube, Jr., Baltimore, MD (US)
Assigned to BC3 TECHNOLOGIES, INC., Baltimore, MD (US)
Filed by BC3 Technologies, Inc., Baltimore, MD (US)
Filed on Feb. 4, 2019, as Appl. No. 16/266,170.
Claims priority of provisional application 62/626,414, filed on Feb. 5, 2018.
Prior Publication US 2019/0240249 A1, Aug. 8, 2019
Int. Cl. A61K 31/722 (2006.01); A61K 9/00 (2006.01); A61K 9/12 (2006.01); A61K 9/14 (2006.01); A61K 9/70 (2006.01); A61K 47/36 (2006.01); A61L 15/00 (2006.01)
CPC A61K 31/722 (2013.01) [A61K 9/0014 (2013.01); A61K 9/12 (2013.01); A61K 9/124 (2013.01); A61K 9/146 (2013.01); A61K 9/7015 (2013.01); A61K 47/36 (2013.01); A61L 15/00 (2013.01)] 22 Claims
 
1. A hemostatic material for application to a wound of a human or an animal, the hemostatic material comprising at least a first part consisting of a native chitosan base and a second part consisting of a salt of the native chitosan base, wherein:
the first part has a chemically modified surface which forms the second part as a surface layer thereon such that chitosan polymers of the first and second parts are interpenetrating and the first part is at least partially encapsulated by the second part, and the surface layer is configured to provide enhanced binding capacity with blood components as compared with a physical mixture of the native chitosan base and salt of the native chitosan base;
the first part is at least partially non-soluble in water and the second part is at least partially soluble in water;
the first and second parts are essentially non-soluble in blood; and
the first and the second parts form at least 50% of a total weight of the hemostatic material.